Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;5(8):861-73.
doi: 10.1517/17425250903012360.

Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression

Satyanarayana R Pondugula  1 , Hanqing Dong, Taosheng Chen
Affiliations
Review

Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression

Satyanarayana R Pondugula et al. Expert Opin Drug Metab Toxicol. 2009 Aug.

Abstract

Background: The expression of drug-metabolizing enzymes CYPs is controlled by pregnane X receptor (PXR), and, therefore, understanding how PXR modulates CYP expression is important to minimize adverse drug interactions, one type of preventable adverse drug reaction.

Objective: We review the mechanisms of PXR-mediated repression of CYP expression.

Methods: We discuss the clinical implications of CYP repression and the role of signal cross-talks, including protein-protein interactions and phosphorylation of PXR and coregulators, in inhibiting PXR and repressing CYP expression.

Results/conclusion: Kinases such as cyclin-dependent kinase 2, protein kinase A, PKC and 70 kDa form of ribosomal protein S6 kinase repress CYP expression by phosphorylating and inhibiting PXR. Growth factor signaling represses CYP expression by phosphorylating and inhibiting forkhead in rhabdomyosarcoma, a co-activator of PXR. During inflammation, NF-kappaB represses both PXR and CYP expression through protein-protein interactions with the PXR pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of target gene induction by PXR. (A) A schematic comparison of the domain structures of a steroid receptor and PXR. AF-1, activation function 1; DBD, DNA binding domain; H, hinge region; LBD, ligand binding domain; AF-2, transactivation function 2. (B) A current model of PXR-mediated gene regulation. Ligand binding induces a dissociation of co-repressors, recruitment of co-activators and contributes to chromatin remodeling and transcriptional activation. Signaling molecules (e.g., protein kinases, phosphatases, or transcription factors) contribute to regulating the function of PXR. XREM, xenobiotic responsive enhancer module.
See this image and copyright information in PMC

References

    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004 May 18;140(10):795–801. - PubMed
    1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255–9. - PubMed
    1. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991 Feb 7;324(6):377–84. - PubMed
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200–5. - PubMed
    1. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995 Oct 9;155(18):1949–56. - PubMed

Publication types

MeSH terms